Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials.
Heinicke T, Krahl R, Kahl C, Cross M, Scholl S, Wolf HH, Hähling D, Hegenbart U, Peter N, Schulze A, Florschütz A, Schmidt V, Reifenrath K, Zojer N, Junghanss C, Sayer HG, Maschmeyer G, Späth C, Hochhaus A, Fischer T, Al-Ali HK, Niederwieser D.
Heinicke T, et al. Among authors: kahl c.
Ann Hematol. 2021 Sep;100(9):2387-2398. doi: 10.1007/s00277-021-04565-1. Epub 2021 Jul 7.
Ann Hematol. 2021.
PMID: 34232360
Free PMC article.
Clinical Trial.